

11. The pharmaceutical composition of claim **10**, wherein said first sequence of said dsRNA is selected from the group consisting of the sense sequences of Table 2 and said second sequence is selected from the group consisting of the anti-sense sequences of Table 2.

12. The pharmaceutical composition of claim **10**, wherein said first sequence of said dsRNA consists of the sequence of SEQ ID NO: 1029, and said second sequence consists of the sequence of SEQ ID NO: 1030.

13. A method for inhibiting the expression of a gene from an Ebola virus in a cell, the method comprising:

- (a) introducing into the cell a double-stranded ribonucleic acid (dsRNA) of claim **1**; and
- (b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of a gene from the Ebola virus, thereby inhibiting expression of a gene from the Ebola virus in the cell.

14. A method of treating, preventing or managing pathological processes mediated by Ebola expression comprising administering to a patient in need of such treatment, prevention or management a therapeutically or prophylactically effective amount of a dsRNA of claim **1**.

15. A vector for inhibiting the expression of a gene from the Ebola virus in a cell, said vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes the dsRNA of claim **1**.

16. A cell comprising the vector of claim **15**.

17. The dsRNA of claim **1**, wherein the dsRNA targets the VP35 of Ebola.

18. The dsRNA of claim **1**, wherein the dsRNA has a sense strand consisting of the sequence of SEQ ID NO:1029, and antisense strand consisting of the sequence of SEQ ID NO:1030.

19. The dsRNA of claim **1**, wherein said dsRNA, upon contact with a cell infected with Ebola virus, inhibits expression of a gene from the virus by at least 40%.

20. The dsRNA of claim **1**, wherein said region of complementarity is 15-30 nucleotides in length.

21. The dsRNA of claim **1**, wherein said region of complementarity is 19 and 24 nucleotides in length.

22. The vector of claim **15**, wherein said dsRNA, upon contact with a cell infected with Ebola virus, inhibits expression of a gene from the virus by at least 40%.

23. The vector of claim **15**, wherein said dsRNA is 15-30 base pairs in length.

24. The vector of claim **15**, wherein said dsRNA is 19-24 base pairs in length.

25. A method of increasing life-span of a subject infected with an Ebola virus, comprising administering to the subject a dsRNA of claim **1** in an amount sufficient to increase the life-span of the subject.

26. A method of decreasing viral titre in a subject infected with an Ebola virus, comprising administering to the subject a dsRNA of claim **1** in an amount sufficient to decrease viral titre in the subject.

27. A method of sustaining platelet count in a subject infected with an Ebola virus, comprising administering to the subject a dsRNA of claim **1** in an amount sufficient to sustain platelet count.

28. The method of claim **27**, wherein the lymphocyte count of the subject is also sustained.

* * * * *